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Communicating with palliative care patients nearing the 
end of life, their families and carers 
Archer W., Latif A., Faull C. 
 
Subtitle: 
Pharmacists are becoming increasingly involved in palliative care and can be a source of 
important information and support for patients at the end of life. Health professionals caring 
for patients with advanced illness should develop skills for communicating with patients, and 
their families and carers. 
 
Effective communication with patients lies at the heart of good healthcare, is associated with 
increased levels of satisfaction and may improve clinical outcomes. Sensitive, honest and 
empathic communication may, in part, relieve the burden of difficult treatment decisions, and 
the physical and emotional complexities of death and dying, and lead to positive outcomes 
for people nearing the end of life (EoL) and their companions[1],[2],[3],[4]. By contrast, poor 
communication is associated with distress and complaints[5],[6],[7],[8], and aggravated by 
resource constraints and increasing work pressures owing to an ageing population with 
chronic conditions and complex care needs[9]. An emerging body of empirical work that 
utilises conversation analysis details the unique challenges encountered by healthcare 
professionals when communicating with patients nearing the EoL[10],[11],[12],[13],[14],[15],[16]. 
However, the precise nature of EoL interaction in pharmacy settings is unknown — a focus 
on traditional counselling interactions in hospital- or community-based 
pharmacy[17],[18],[19],[20] means that the explicit details of EoL discussions between pharmacists 
and their patients, relatives and carers has been largely undocumented. 
 
This article focuses on the communication skills associated with the pharmacist’s extended 
role in palliative care, with specific reference to the skills involved in communicating with 
people who are approaching EoL, their families and carers. This is an increasingly relevant 
topic in light of pharmacists’ involvement in palliative care services both nationally and 
globally[21],[22],[23],[24],[25],[26]. 
 
Role of the pharmacist in palliative care 
The medical needs of palliative care patients and their carers are often complex and 
protracted[23]. Pharmacists’ expert pharmaceutical knowledge and broad skill set — coupled 
with their widespread accessibility and trusted relationships with patients and carers — mean 
that they are well suited to better integration within the palliative care team[22],[25]. The 
pharmacist’s role is extending beyond the more traditional elements of dispensing activity 
and management of minor ailments towards the provision of greater psychosocial support for 
patients[22],[26]. This creates opportunities for further interaction, not only with patients, but 
also with loved ones, relatives and carers. 
 
Pharmacists should have a clear understanding of the unique challenges associated with 
palliative care-related interactions, such as ongoing assessment, clarification of clinical 
options where there is uncertainty, pharmacotherapeutic monitoring of the patient’s 
condition, as well as offering advice and support for patients, relatives and carers[25]. 
Pharmacists need to be mindful that this is an emotionally difficult time for patients, relatives 
and carers which, for the latter two groups, may extend beyond the patient’s death and into 
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the bereavement period. Pharmacists must, therefore, adapt their communication skills to 
demonstrate compassion and empathy. Moreover, they will need to work closely with the 
multi-disciplinary team, including the palliative care teams in outpatient, inpatient and 
hospice services, to ensure that patient care is not delivered in therapeutic silos, but is 
integrated throughout. 
 
How pharmacists should communicate and have open discussions with the patient, 
carers and their families 
EoL is seen as the last year of a person’s life with an advanced, progressive illness or, more 
likely, a number of comorbidities. The government’s EoL strategy sets out its 
recommendations governing the six key elements that characterise the EoL pathway[27] (see 
‘Figure 1: Department of Health: End of life (EoL) care pathway’). 
 
Figure 1 Department of Health: End of Life (EoL) care pathway;  
The six key elements of an EoL pathway. It is important that support for carers and families, 




The point at which discussions around EoL care are undertaken varies from person to person, 
but open and honest communication that is sensitive to the situation, commences early and 
continues through the patient’s journey, is crucial. Consistent with the key skills that are 
fundamental to effective communication in any clinical encounter[28], the aims of such 
discussions include: 
• Eliciting the patient’s level of understanding, main problem(s) or concern(s) about their 
medicines (especially those that are anticipatory) and any impact (physical, emotional 
or social) that these are having on the patient; 
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• Determining how much information the patient wishes to receive and providing this to 
ensure medicine optimisation; 
• Ascertaining whether the patient wishes more support to engage in medicine or EoL 
conversations with other family members or carers. 
 
An e-learning programme produced by Health Education England for End of Life Care (e-
ELCA) includes sessions focusing on communication skills development[29]. Clinical 
guidance further elaborates on the skills required, including the importance of an 
individualised, patient-centred approach in which patients are treated respectfully, with 
kindness, dignity, compassion and understanding, and in which their needs, fears or concerns 
about EoL are listened to and discussed in a sensitive, non-judgmental manner[30]. 
 
Through timely identification of patients who are at risk of deteriorating and dying, and in the 
last year of life, healthcare professionals can tailor information and provide opportunities for 
patients to consider their choices for care. Patients want choices relating to seven key themes 
(see ‘Box 1: Patients’ preferences for choices at the end of life’)[31]. 
 
Box 1: Patients’ preferences for choices at the end of life (EoL) 
 





It may be helpful to signpost some patients to advice about drawing up an advance statement 
of wishes and preferences or an advance decision to refuse treatment, or to information about 
how to appoint someone with a lasting power of attorney (LPA) should they lose capacity to 
make their own decisions (see ‘Additional resources’). 
 
Pharmacists will also need to develop strategies for supporting the patient’s relatives or 
carers, who may be involved in enabling the patient to make choices or communicate their 
wishes. General Medical Council (GMC) guidance states that family members may be 
directly involved in the patient’s treatment or care, and in need of relevant information to 
help them care for, recognise and respond to changes in the patient’s condition[32]. In cases 
where patients may lack capacity, pharmacists can facilitate talk about the patient’s likely 
wishes, beliefs and values regarding treatment. However, pharmacists will need to be skilful 
to ensure that relatives or carers do not think themselves, or have the burden of being, the 
decision-maker if they lack the delegated authority of an attorney (LPA). 
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In a summary of evidence-based techniques for communicating with patients and family 
members, LeBlanc and Tulsky identify core communication strategies that include[33]: 
• Using open-ended questions; 
• Soliciting agendas early in the interaction; 
• Asking permission to raise particular topics; 
• Using verbal and non-verbal expressions of empathy; 
• Using praise; 
• Using ‘wish’ statements; 
• Aligning with the hopes of patients, loved ones and carers through the use of ‘hope for the 
best’ phraseology. 
 
Explaining clinical options, and risks and benefits 
Patients with advanced illness are usually receiving complicated treatment regimes consisting 
of multiple doses of medicines and formulations. Pharmacists will need to explore the best 
ways to communicate such information, especially where the patient’s first language is not 
English, the patient is a child, or the patient is suffering from a condition that reduces their 
cognitive function. Such communication might need to involve supplementing written 
information with symbols or visual images (e.g. pictures of tablets), using jargon-free 
explanations, as well as providing options for regular contact. 
 
When discussing treatments, pharmacists should: help patients (and relatives or carers) 
understand the purpose of a medicine and how it is optimally used; elicit and answer 
questions; discuss the risks, benefits and consequences of treatments; minimise side effects 
and maximise safety; allay fears about opioid medications and their use; offer adherence 
strategies (e.g. dosette boxes) and strategies to reduce stress (e.g. prescription collection and 
delivery); and review medications to highlight potential interactions and those that may no 
longer be of value. 
 
When discussing the risks and benefits of treatment and the use of strong opioids, 
pharmacists should be aware of the recommendations and strategies in current clinical 
guidance[30],[34] (see boxes 2 and 3). 
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Box 2: National Institute for Health and Care Excellence (NICE). Clinical guideline [CG138]. Patient 
experience in adult NHS services: improving the experience of care for people using adult NHS 
services 
 
Source: Reproduced with permission of National Institute for Health and Care Excellence; 
https://www.nice.org.uk/guidance/cg138/chapter/1-guidance   
 
 
Box 3: National Institute for Health and Care Excellence (NICE). Clinical Guideline [CG140]. Palliative 
care for adults: strong opioids for pain relief 
 
Source: Reproduced with permission of National Institute for Health and Care Excellence; 
https://www.nice.org.uk/guidance/cg140/chapter/1-recommendations 
 
Managing patients who are not emotionally ready to discuss their future care 
Patients with advanced illness are often required to make complex decisions about treatment 
and care that may require consideration of risks and benefits, or decisions about whether a 
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particular course of action should be discontinued. GMC guidance advises healthcare 
professionals to ensure that patients have opportunities to discuss the options available to 
them and what treatment (or refusal) is likely to involve[32]. While some patients will be able 
to engage in EoL discussions, others may be less willing to think about future issues or may 
find the prospect of thinking about deterioration and dying too distressing. All healthcare 
professionals and pharmacists will find it challenging to engage such patients in discussion 
about future treatment and ‘what if?’ scenarios. Pharmacists will need to develop strategies 
that enable them to deal with these discussions. As recent research has shown, this requires 
skilful techniques that rely on the patient’s use of verbal or non-verbal cues in order to 
explore the concerns of patients, their relatives or carers in ways that allow patients to raise 
EoL considerations when they are ready[16]. Where patients wish to nominate a relative or 
carer to have these discussions, it is important to support their wishes and establish their 
consent. 
 
Managing expectations among patients, relatives and carers 
Particular difficulties may arise in settings where families or carers are involved in planning 
ongoing care, such as in the event of a loss of capacity or in cases where treatment options for 
children or young people need to be discussed. The stresses associated with life-limiting and 
life-threatening illness can give rise to differing opinions over treatment options that can have 
implications for the quality of care (e.g. misunderstanding prognosis, advice and clarity over 
when to administer anticipatory medicines)[33]. Managing expectations or disagreements takes 
time, and patients, their families and carers will need support to arrive at important decisions. 
Advice for recognising, acknowledging and managing divergent views and potential conflict 
has been suggested[33] as a useful negotiating strategy in working towards a consensus[29]. 
 
Managing uncertainty: hoping for the best but preparing for the worst 
For an individual patient, the likely benefits and harms of palliative treatments aimed at 
maintaining disease stability, slowing deterioration or reducing symptoms are uncertain. 
While research may provide pharmacists with medical information about the number needed 
to treat or number needed to harm to achieve a defined outcome for the individual patient, 
this is unpredictable. Enabling patients to appreciate this uncertainty, while supporting their 
need for hope, is a tricky communication task and professionals, in their communication and 
relationships with patients, can enhance or diminish their sense of hope[35] (see ‘Box 4: 
Contrasting communication behaviours’). 
 
Box 4: Contrasting communication behaviours’ 
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Behaviours that demonstrate the valuing of patients as individuals and the enormity of their 
life situation can really help. These behaviours are not simply ‘being nice’. They are 
important therapeutic interventions that promote a sense of hope and preserve a sense of 
dignity, something that many patients fear the loss of[36]. 
 
While a focus on unrealistic hopes (e.g. cure or more time) may not be helpful, a balance of 
hoping for a realistic best (e.g. that the pain will go away with this treatment), while 
preparing for deterioration (e.g. “what we will do if this isn’t sufficient is…”), is the best 
strategy[37],[38],[39]. 
 
Understanding and respect for cultural, religious or spiritual beliefs 
A person’s culture, religious or spiritual beliefs provides them with a framework and ideas 
about health and illness, through which healthcare decisions are made. 
 
Pharmacists need cultural competence to ensure treatment is aligned with these preferences 
and wishes. They can achieve this through seeking clarification from patients and family 
about aspects of their care that may be influenced by their cultural, religious or spiritual 
beliefs. Consider, for example, asking the patient about: 
• Faith: What is important to them? What rituals, books or places for prayer/meditation do 
they need? 
• Diet: Are there any preferred foods or foods that are considered taboo? (e.g. gelatin in 
some capsules is not appropriate for vegetarians, and pork is not considered halal in 
Islam). 
• Touch and respect: Consider any issues that gender differences may provoke. Would the 
patient like to discuss matters alone or with someone else present? 
 
It can be helpful to have insight into traditional practices of different faiths and how this 
influences dying and bereavement. Several useful sessions about working with cultural 
diversity can be found in the e-learning for End of Life Care (e-ELCA) programme[29]. Public 
Health England have recently produced a guide for healthcare professionals working with 
diverse communities[29]. 
 
Recognising the changing needs of the patient and those close to them 
As patients become sicker, their needs and those of their companions increase. Pharmacists 
can make a huge difference to the stress and satisfaction that families experience by offering 
practical support. Strategies that anticipate needs and offer solutions are appreciated. 
Remaining professional but also demonstrating understanding and compassion can help 
families who can sometimes find it more difficult to cope with their emotions when people 
are ‘too nice’ (e.g. asking them how they are). For example: 
• Would it help if I put the tablets for each time and day in an easy to remember pack? 
• I can make an arrangement for the GP to send prescriptions directly to me if that helps 
you? I can dispose of the old medicines if you can bring them in. 
 
Effective communication with patients is central to the goal of medicines optimisation. 
Following often simple strategies and techniques on how to manage difficult situations will 
improve pharmacists’ confidence and ensure patients’, carers’ and families’ medicine needs 
at the EoL are fully acknowledged and met. 
 
Additional resources: 
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• NHS. Health Education England. e-Learning for End of Life Care (e-ELCA) 
• NHS Choices. Planning ahead for the end of life 
• NHS. Improving Quality. Planning for your future care – a guide 
• Public Health England. Faith at end of life: a resource for professionals, providers and 
commissioners working in communities 
• National Institute for Health and Care Excellence (NICE). NICE guideline [NG31]. Care 
of dying adults in the last days of life 
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